O número de mortes relacionadas à doença de Chagas é estimado em 10,000 a 12,500 por ano.[27]World Health Organization. Chagas disease in Latin America: an epidemiological update based on 2010 estimates. Wkly Epidemiol Rec. 2015 Feb 6;90(6):33-43.
https://iris.who.int/bitstream/handle/10665/242316/WER9006_33-44.PDF?sequence=1&isAllowed=y
http://www.ncbi.nlm.nih.gov/pubmed/25671846?tool=bestpractice.com
[28]TDR. Report of the scientific working group on Chagas disease, 17-20 April 2005 [in Spanish]. Buenos Aires, Argentina; 2007.
https://iris.who.int/bitstream/handle/10665/69724/TDR_SWG_09_spa.pdf?sequence=1&isAllowed=y
[29]Moncayo A, Silveira AC. Current epidemiological trends for Chagas disease in Latin America and future challenges in epidemiology, surveillance and health policy. Mem Inst Oswaldo Cruz. 2009;104(suppl 1):17-30.
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762009000900005&lng=en&nrm=iso&tlng=en
http://www.ncbi.nlm.nih.gov/pubmed/19753454?tool=bestpractice.com
[219]Jannin J, Salvatella R, eds. Estimacion cuantitativa de la enfermedad de Chagas en las Americas. Montevideo, Uruguay: OPS/HDM/CD/425-06; 2006:28. Estimam-se 546,000 a 806,000 anos de vida perdidos ajustados por incapacidade.[220]Murray CJ, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012 Dec 15;380(9859):2197-223.
http://www.ncbi.nlm.nih.gov/pubmed/23245608?tool=bestpractice.com
[221]Lee BY, Bacon KM, Bottazzi ME, et al. Global economic burden of Chagas disease: a computational simulation model. Lancet Infect Dis. 2013 Apr;13(4):342-8.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3763184
http://www.ncbi.nlm.nih.gov/pubmed/23395248?tool=bestpractice.com
[222]World Health Organization. World Health Report 2004: changing history. Geneva: WHO; 2004:120-1,126-7.
http://www.who.int/whr/2004/en/report04_en.pdf
O tratamento antiparasitário é quase 100% eficaz para curar a doença, mas só quando administrado o mais rápido possível após a infecção, no início da fase aguda. A eficácia diminui com o tempo de infecção. As taxas de morbidade e mortalidade nos pacientes com transmissão oral são mais elevadas que nos casos agudos causados por outras formas de transmissão.[9]Shikanai-Yasuda MA, Carvalho NB. Oral transmission of Chagas disease. Clin Infect Dis. 2012 Mar;54(6):845-52.
https://academic.oup.com/cid/article/54/6/845/290317
http://www.ncbi.nlm.nih.gov/pubmed/22238161?tool=bestpractice.com
O prognóstico geral entre pacientes que se encontram na fase indeterminada é excelente.[72]Hasslocher-Moreno AM, Xavier SS, Saraiva RM, et al. Indeterminate form of Chagas disease: historical, conceptual, clinical, and prognostic aspects. Rev Soc Bras Med Trop. 2021;54:e02542021.
https://www.scielo.br/j/rsbmt/a/XdBqRnywwhwm5y3pqFF5HTH/?lang=en
http://www.ncbi.nlm.nih.gov/pubmed/34320133?tool=bestpractice.com
[127]Meymandi S, Hernandez S, Park S, et al. Treatment of Chagas disease in the United States. Curr Treat Options Infect Dis. 2018 Jun 26;10(3):373-88.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6132494
http://www.ncbi.nlm.nih.gov/pubmed/30220883?tool=bestpractice.com
De 10 a 20 anos após a fase aguda, a forma indeterminada evolui para cardiomiopatia a uma taxa anual de 1.9%.[223]Chadalawada S, Sillau S, Archuleta S, et al. Risk of chronic cardiomyopathy among patients with the acute phase or indeterminate form of Chagas disease: a systematic review and meta-analysis. JAMA Netw Open. 2020 Aug 3;3(8):e2015072.
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2770045
http://www.ncbi.nlm.nih.gov/pubmed/32865573?tool=bestpractice.com
Os pacientes que tiverem tido doença de Chagas aguda sintomática, mas que não tiverem recebido tratamento tripanocida, enfrentam maior risco de evoluir para a forma cardíaca, com uma taxa de progressão anual estimada de 4.6%.[2]Nunes MCP, Beaton A, Acquatella H, et al. Chagas cardiomyopathy: an update of current clinical knowledge and management: a scientific statement from the American Heart Association. Circulation. 2018 Sep 18;138(12):e169-209.
https://www.ahajournals.org/doi/full/10.1161/CIR.0000000000000599?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed
http://www.ncbi.nlm.nih.gov/pubmed/30354432?tool=bestpractice.com
[223]Chadalawada S, Sillau S, Archuleta S, et al. Risk of chronic cardiomyopathy among patients with the acute phase or indeterminate form of Chagas disease: a systematic review and meta-analysis. JAMA Netw Open. 2020 Aug 3;3(8):e2015072.
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2770045
http://www.ncbi.nlm.nih.gov/pubmed/32865573?tool=bestpractice.com
A cardiomiopatia é a principal causa de morte entre pacientes com a forma cardíaca da doença crônica, devido à insuficiência cardíaca, AVC cardioembólico ou morte súbita.[4]Dias JC, Ramos AN Jr, Gontijo ED, et al. 2 nd Brazilian Consensus on Chagas disease, 2015. Rev Soc Bras Med Trop. 2016 Dec;49Suppl 1(Suppl 1):3-60.
https://www.scielo.br/j/rsbmt/a/mNgRbrGjpwwc9dSF73PdMHt/?lang=en
http://www.ncbi.nlm.nih.gov/pubmed/27982292?tool=bestpractice.com
[13]Brazilian Ministry of Health. Brazilian consensus on Chagas disease [in Portuguese]. Rev Soc Bras Med Trop. 2005;38(suppl 3):7-29.
http://www.ncbi.nlm.nih.gov/pubmed/16416933?tool=bestpractice.com
[14]Andrade JP, Marin Neto JA, Paola AA, et al. I Latin American guidelines for the diagnosis and treatment of Chagas' heart disease: executive summary. Arq Bras Cardiol. 2011 Jun;96(6):434-42.
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2011000600002&lng=en&nrm=iso&tlng=en
http://www.ncbi.nlm.nih.gov/pubmed/21789345?tool=bestpractice.com
[224]Saraiva RM, Mediano MFF, Mendes FS, et al. Chagas heart disease: an overview of diagnosis, manifestations, treatment, and care. World J Cardiol. 2021 Dec 26;13(12):654-75.
https://www.wjgnet.com/1949-8462/full/v13/i12/654.htm
http://www.ncbi.nlm.nih.gov/pubmed/35070110?tool=bestpractice.com
A taxa de letalidade nos pacientes com reativação é elevada, especialmente nos casos de diagnóstico tardio.[6]Shikanai-Yasuda MA, Mediano MFF, Novaes CTG, et al. Clinical profile and mortality in patients with T. cruzi/HIV co-infection from the multicenter data base of the "Network for healthcare and study of Trypanosoma cruzi/HIV co-infection and other immunosuppression conditions". PLoS Negl Trop Dis. 2021 Sep 30;15(9):e0009809.
https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0009809
http://www.ncbi.nlm.nih.gov/pubmed/34591866?tool=bestpractice.com
[8]Shikanai-Yasuda MA, de Almeida EA, López MC, et al. Chagas disease: a parasitic infection in an immunosuppressed host. Springer, Cham. 2020 Jul 21;213-34.[225]Martins-Melo FR, Alencar CH, Ramos AN Jr, et al. Epidemiology of mortality related to Chagas' disease in Brazil, 1999-2007. PLoS Negl Trop Dis. 2012;6(2):e1508.
http://www.plosntds.org/article/info%3Adoi%2F10.1371%2Fjournal.pntd.0001508
http://www.ncbi.nlm.nih.gov/pubmed/22348163?tool=bestpractice.com
O diagnóstico deve ser feito com rapidez, pois a administração precoce do tratamento específico melhora o prognóstico de forma considerável.[4]Dias JC, Ramos AN Jr, Gontijo ED, et al. 2 nd Brazilian Consensus on Chagas disease, 2015. Rev Soc Bras Med Trop. 2016 Dec;49Suppl 1(Suppl 1):3-60.
https://www.scielo.br/j/rsbmt/a/mNgRbrGjpwwc9dSF73PdMHt/?lang=en
http://www.ncbi.nlm.nih.gov/pubmed/27982292?tool=bestpractice.com
[8]Shikanai-Yasuda MA, de Almeida EA, López MC, et al. Chagas disease: a parasitic infection in an immunosuppressed host. Springer, Cham. 2020 Jul 21;213-34.
Os critérios para cura são baseados na obtenção da sorologia negativa. O tempo para atingir a sorologia negativa varia dependendo da fase da doença: de 3-5 anos, na fase aguda da doença de Chagas; cerca de 1 ano, na infecção congênita; de 5-10 anos, na fase crônica da doença recente; e ≥20 anos, na fase crônica da doença em longo prazo.[168]Centers for Disease Control and Prevention. Parasites - American trypanosomiasis (also known as Chagas disease): congenital chagas disease. Jun 2021 [internet publication].
https://www.cdc.gov/parasites/chagas/health_professionals/congenital_chagas.html
[226]Alvarez MG, Bertocchi GL, Cooley G, et al. Treatment success in Trypanosoma cruzi infection is predicted by early changes in serially monitored parasite-specific T and B cell responses. PLoS Negl Trop Dis. 2016 Apr;10(4):e0004657.
https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0004657
http://www.ncbi.nlm.nih.gov/pubmed/27128444?tool=bestpractice.com
Na fase crônica, pode ocorrer uma queda sustentável e progressiva dos títulos sorológicos (≥3 diluições nos títulos sorológicos), sugerindo uma futura sorologia negativa. Em qualquer estágio da evolução da doença, um teste parasitológico positivo indica falha no tratamento. Em geral não se observa a cura espontânea dos casos crônicos da doença de Chagas, embora tenham sido documentados alguns casos na Costa Rica, no Uruguai e no Brasil.[227]Zeledón R, Dias JC, Brilla-Salazar A, et al. Does a spontaneous cure for Chagas' disease exist? Rev Soc Bras Med Trop. 1988 Jan-Mar;21(1):15-20.[228]Francolino SS, Antunes AF, Talice R, et al. New evidence of spontaneous cure in human Chagas' disease. Rev Soc Bras Med Trop. 2003 Jan-Feb;36(1):103-7.
https://www.scielo.br/j/rsbmt/a/mL864yGPVMnVsxqVL4ZvD7q/?lang=en
http://www.ncbi.nlm.nih.gov/pubmed/12715069?tool=bestpractice.com
[229]Dias JC, Dias E, Martins-Filho OA, et al. Further evidence of spontaneous cure in human Chagas disease. Rev Soc Bras Med Trop. 2008 Sep-Oct;41(5):505-6.
https://www.scielo.br/j/rsbmt/a/5RkJswMKGFfMGYCsnhYxQHP/?lang=en
http://www.ncbi.nlm.nih.gov/pubmed/19009195?tool=bestpractice.com